Risk of basal cell carcinoma in a randomized clinical trial of aspirin and folic acid for the prevention of colorectal adenomas.

ABSTRACT:

Background

Aspirin may reduce the risk of several types of cancer.

Objectives

To evaluate if folic acid is associated with risk of basal cell carcinoma (BCC).

Methods

BCC incidence was evaluated in a randomized, double-blind, placebo-controlled clinical trial of aspirin (81 mg daily or 325 mg daily for ~3 years) and/or folic acid (1 mg daily for ~6 years) for the prevention of colorectal adenomas among 1121 participants with a previous adenoma. BCC was confirmed by blinded review of pathology reports.

Results

One hundred and four of 958 non-Hispanic white participants were diagnosed with BCC over a median follow-up of 13·5 years. Cumulative incidence of BCC was 12% [95% confidence interval (CI) 7-17] for placebo, 16% (95% CI 11-21) for 81 mg aspirin daily and 1

SUBMITTER: Passarelli MN 

PROVIDER: S-EPMC6108912 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature